

# United States of America

United States Patent and Trademark Office

## RHUDEX

**Reg. No. 5,812,401**

**Registered Jul. 23, 2019**

**Int. Cl.: 5, 10, 42**

**Service Mark**

**Trademark**

**Principal Register**

Medigene AG (GERMANY aktiengesellschaft )  
Lochhamer Str. 11  
Planegg-martinsried, FED REP GERMANY 82152

CLASS 5: Antibodies, proteins, T cell proteins and peptides for medical use, monoclonal antibodies for clinical or medical use, pharmaceutical and biochemical substances and preparations, namely, small molecules, and CD80 antagonists for the treatment of cancer, rheumatoid arthritis and auto-immune diseases; in vivo immunotherapeutic, immunoprophylactic and immunodiagnostic agents, preparations and substances for clinical or medical use; vaccines; protein conjugates; diagnostic and analytical preparations for medical and veterinary use, namely, products to diagnose and analyze tissue damage caused by inflammation due to auto-immune diseases; enzymes and enzyme preparations for clinical or medical use and the treatment of cancer, rheumatoid arthritis and auto-immune diseases; chemical products for use in medical science, namely, T-cell receptors, small molecule and protein therapeutics; pre-filled vials containing pharmaceuticals and bioceuticals, namely, small molecules and protein therapeutics involving T-cell receptors for the treatment of cancer, rheumatoid arthritis and auto-immune diseases

CLASS 10: Apparatus and instruments for diagnostic and therapeutic research, namely, instruments for measuring tissue damage or movement in limbs or organs; display apparatus, namely, multi-well plates and arrays for medical or clinical diagnosis and analysis; surgical and medical apparatus and instruments, namely, injectors and syringes

CLASS 42: Biotechnology services, namely, the development of T-cell receptor pharmaceutical products and technologies for the treatment of cancer, rheumatoid arthritis, inflammatory and auto-immune diseases; scientific and medical research and development of new technology for others in the field of biotechnology and genomics, pharmaceutical drug development services, and pharmaceutical product development; genetic engineering services, licensing intellectual property, namely, trademarks and patents in the field of biotechnology

THE MARK CONSISTS OF STANDARD CHARACTERS WITHOUT CLAIM TO ANY PARTICULAR FONT STYLE, SIZE OR COLOR

OWNER OF EUROPEAN UNION , REG. NO. 003315546, DATED 11-03-2009, EXPIRES 08-11-2023

OWNER OF U.S. REG. NO. 4322812

SER. NO. 88-245,830, FILED 12-31-2018



*Andrei Iancu*

Director of the United States  
Patent and Trademark Office

**REQUIREMENTS TO MAINTAIN YOUR FEDERAL TRADEMARK REGISTRATION**

**WARNING: YOUR REGISTRATION WILL BE CANCELLED IF YOU DO NOT FILE THE DOCUMENTS BELOW DURING THE SPECIFIED TIME PERIODS.**

**Requirements in the First Ten Years\***

**What and When to File:**

- **First Filing Deadline:** You must file a Declaration of Use (or Excusable Nonuse) between the 5th and 6th years after the registration date. See 15 U.S.C. §§1058, 1141k. If the declaration is accepted, the registration will continue in force for the remainder of the ten-year period, calculated from the registration date, unless cancelled by an order of the Commissioner for Trademarks or a federal court.
- **Second Filing Deadline:** You must file a Declaration of Use (or Excusable Nonuse) and an Application for Renewal between the 9th and 10th years after the registration date.\* See 15 U.S.C. §1059.

**Requirements in Successive Ten-Year Periods\***

**What and When to File:**

- You must file a Declaration of Use (or Excusable Nonuse) and an Application for Renewal between every 9th and 10th-year period, calculated from the registration date.\*

**Grace Period Filings\***

The above documents will be accepted as timely if filed within six months after the deadlines listed above with the payment of an additional fee.

**\*ATTENTION MADRID PROTOCOL REGISTRANTS:** The holder of an international registration with an extension of protection to the United States under the Madrid Protocol must timely file the Declarations of Use (or Excusable Nonuse) referenced above directly with the United States Patent and Trademark Office (USPTO). The time periods for filing are based on the U.S. registration date (not the international registration date). The deadlines and grace periods for the Declarations of Use (or Excusable Nonuse) are identical to those for nationally issued registrations. See 15 U.S.C. §§1058, 1141k. However, owners of international registrations do not file renewal applications at the USPTO. Instead, the holder must file a renewal of the underlying international registration at the International Bureau of the World Intellectual Property Organization, under Article 7 of the Madrid Protocol, before the expiration of each ten-year term of protection, calculated from the date of the international registration. See 15 U.S.C. §1141j. For more information and renewal forms for the international registration, see <http://www.wipo.int/madrid/en/>.

**NOTE: Fees and requirements for maintaining registrations are subject to change. Please check the USPTO website for further information. With the exception of renewal applications for registered extensions of protection, you can file the registration maintenance documents referenced above online at <http://www.uspto.gov>.**

**NOTE: A courtesy e-mail reminder of USPTO maintenance filing deadlines will be sent to trademark owners/holders who authorize e-mail communication and maintain a current e-mail address with the USPTO. To ensure that e-mail is authorized and your address is current, please use the Trademark Electronic Application System (TEAS) Correspondence Address and Change of Owner Address Forms available at <http://www.uspto.gov>.**